Tatsis Ourania's Form 4 filing
Vertex Pharmaceuticals IncVRTX · filed Feb 18, 2026
- Accession no.
- 0000875320-26-000076
- Filed
- Feb 18, 2026
- Trade date
- Feb 13, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $750.0K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tatsis OuraniaCIK 0001789815 | Officer (EVP, Chief Reg. & Quality Off.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Open market sales reported on this line occurred at a weighted average price of $499.99 (range $499.99 to $500.04).
Referenced by the price of 1 transaction in Table I.
- F3
Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.